Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
For the full year, sales was INR 745.73 million compared to INR 588.34 million a year ago. Revenue was INR 773.88 million compared to INR 600.3 million a year ago. Net income was INR 185.37 million compared to INR 44.07 million a year ago. Basic earnings per share from continuing operations was INR 16.93 compared to INR 26.21 a year ago. Diluted earnings per share from continuing operations was INR 16.93 compared to INR 26.21 a year ago.